Integrating Our Acoustic Solutions into Your Processes

Explore Acoustic Cell Handling in Your Process

Modular Type Package (MTP) offer

Aenitis offers Modular Type Package (MTP) business solutions to enable the seamless integration of acoustic cell handling steps into your existing bioprocess workflows.
This approach allows our technology to be embedded at any stage; sorting, washing, isolation, or concentration; providing flexible, scalable, and GMP-ready solutions tailored to your process.

Collaboration models include:

  • Co-development from proof-of-concept to GMP manufacturing
  • Custom consumable production for existing platforms
  • Licensing of our acoustic technology
  • Rapid user training (approximately 30 minutes for full autonomy)
  • Designed collaboratively with research laboratories for intuitive usability
Built to Scale

Modular Production and Scalability

Aenitis is developing a flexible and modular manufacturing approach based on a modular factory capabilities allowing rapid design and manufacturing of single-use custom consumables in compliance with GMP standards and adapted to CGT volumes needs:

  • Prototype in as little as 1 month
  • Serial production within 4 months, plus regulatory validation (biocompatibility, cytotoxicity, etc.)
  • Demonstrated scalability from custom designs to mass-produced plastic injection components
  • Scaling to more conventional full plastic injection production should require 12–18 months, including mould development and regulatory qualification if need (GMP compliance)
  • Production leverages 3D printing for plastic parts, automation for assembly and testing, and sheet metal fabrication for metallic components

This approach enables faster, cost-effective production of tailored consumables, a key advantage for advanced therapies where traditional injection molding is too slow or inflexible.

Key Differentiators

  • Scientifically and technically validated solution
  • Scalable to industrial production levels
  • Flexible, modular manufacturing approach
  • Rapid customization capabilities
The technology represents a disruptive approach to bioprocessing, offering enhanced flexibility and efficiency in cell and gene therapy applications.

Ready to try?

We invite you to define your specific needs for gentle acoustophoresis cell processing. Together, we’ll co-develop a solution that fits your cell or gene therapy process:

Please fill this form and we will get back to you as soon as possible

Aenitis development pipeline

Collaborative or MTP developments
Own developments
Projects
Objectives
Proof of concept
Development
Industrial dev. & prod.
Upcoming expected milestone
Early
Advanced POC
Development Feasability
Advanced POC
Advanced POC
Acoustic cell handling lab instruments

Versatile devices for lab purpose. Increase recovery yield. Less cells damaged – MitisTM

New production facility for disposables in Modular Plant

Platelets isolation from PRP: No platelet activation

Project on standby due to change in MDR in EU and lack of notified body + Mature Market warnings

Rare and complex cell sorting « acoustic beads »

Induce low density on targeted cells in flow: Isolation of TL with mAB anti-CD3 from PBMC as a 1st demo. Alternative to magnetic beads

Demo on PBMC expected by Sept. 2025

Gentle Cell concentration

MSC post Bioreactor / Expansion: Increase recovery yield. Less cells damaged

In discussion for moving forward with a new bioreactor type

WBC pre transfection or post expansion: In flow system pre electroporation or sonoporation

Work in progress with Inserm and in parallel with potential industrial partner (confidential)

iPSC post bioreactor / expansion: Increase recovery yield. Less loss. No unexpected activation.

Tests on different type of iPSC to be proceeded by Oct. 2025

Transduction boost

Increase of membrane-vector fusion: Increase transduction yield

Word on reproducibility. 20% to 50% boost.

IPSC washing

In flow washing in perfusion: Increase recovery yield. No cell unexpected activation or loss.

Project linked to an industrial therapeutic cell production plant. Next step will be on a selected iPSC.